• Records first net profit after tax of $214,656
• Achieved $18.4m in sales revenue, up 41.6%
• International sales reached $1.5m, up ~69%
• Launched new brand and 7 novel products in June 2025

Biome Australia Limited (ASX: BIO) is pleased to announce unaudited full-year sales revenue of $18.4 million for FY25, representing 41.6% growth versus the previous corresponding period ($13.01m FY24) and its first net profit after tax of $214,656. The breakthrough year demonstrated exceptional growth across all key metrics, with the company maintaining strong profitability and achieving its sixth consecutive quarter of positive EBITDA. Q4 FY25 marked the strongest quarter to date with sales revenue surpassing $5 million, culminating in a record monthly performance of $2.1 million in June. Biome's Activated Probiotics brand secured the number two position in total probiotic revenue within community pharmacy, with domestic business sell-through increasing by over 50% in FY25. International operations delivered significant growth with $1.5 million in international sales revenue, representing 69% growth versus the previous corresponding period. The company successfully completed its strain development program, identifying and commercializing proprietary probiotic strain Lactobacillus plantarum BMB18, and launched its new Activated Therapeutics platform featuring four specialized products. Biome is confident it is on track for its Vision 27 targets, with a $20 million run-rate entering FY26.

Biome is on track to achieve its Vision 27 forecast of at least $75 million in cumulative sales for FY25-27.

Biome is entering the next phase to becoming a leading global company in probiotics and targeted health solutions for many years to come, with a $20 million annualised sales revenue run rate as FY26 commenced.